0001433714-21-000022.txt : 20210803 0001433714-21-000022.hdr.sgml : 20210803 20210803161006 ACCESSION NUMBER: 0001433714-21-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210803 DATE AS OF CHANGE: 20210803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLIGHT HEALTH, INC. CENTRAL INDEX KEY: 0001433714 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 261989091 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36330 FILM NUMBER: 211139811 BUSINESS ADDRESS: STREET 1: 150 SPEAR STREET STREET 2: SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 415-671-4683 MAIL ADDRESS: STREET 1: 150 SPEAR STREET STREET 2: SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER COMPANY: FORMER CONFORMED NAME: VENTANA HEALTH SERVICES, INC. DATE OF NAME CHANGE: 20090831 FORMER COMPANY: FORMER CONFORMED NAME: MARIA HEALTH INC DATE OF NAME CHANGE: 20080429 8-K 1 cslt-20210803.htm 8-K cslt-20210803
false000143371400014337142021-08-032021-08-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
August 3, 2021
Date of Report (Date of earliest event reported)
CASTLIGHT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware

001-36330
26-1989091

(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer
Identification Number)
150 Spear Street, Suite 400
San Francisco, CA 94105
(Address of principal executive offices)
(415) 829-1400
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
Not applicable

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class B Common Stock, par value $0.0001 per shareCSLTNew York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 2.02.    Results of Operations and Financial Condition.

The information in Item 2.02 of this Current Report, including the accompanying Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing.

On August 3, 2021, Castlight Health, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.

The Company's senior management will host a conference call to discuss the Company's second quarter 2021 results and business outlook on Tuesday, August 3, 2021, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company’s Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367. The conference ID number for the live call and replay is 3859414.

Item 9.01.     Financial Statements and Exhibits.

(d) Exhibits

Exhibit        Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)







SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CASTLIGHT HEALTH, INC.
Date:August 3, 2021By:/s/ Will Bondurant
Will Bondurant
Chief Financial Officer




EX-99.1 2 exh991-pressreleaseq221.htm EX-99.1 Document

image1.jpg
Castlight Health Announces Second Quarter 2021 Results

Company Demonstrates Sequential Increase in ARR


SAN FRANCISCO - August 3, 2021 - Castlight Health, Inc. (NYSE:CSLT), a leading health navigation platform provider, today announced results for its second quarter ended June 30, 2021.

“We had a strong second quarter, achieving the top-end of our revenue guidance and generating our fifth straight quarter of non-GAAP profitability and positive cash flow,” said Maeve O’Meara, chief executive officer of Castlight Health. “We were pleased with pipeline progress, as our late-stage pipeline for the quarter is the largest in four years, we reported a second low churn quarter, and released a third-party study that demonstrated Castlight’s clear value across members at every clinical risk level. We continue to be confident that we will deliver ARR growth in 2021 and are excited about opportunities to extend our data and technology to new markets as part of our long-term growth strategy.”

Financial performance for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 includes:
Total revenue of $35.6 million, compared to $35.5 million
GAAP gross margin of 65.9%, compared to 64.1%
Non-GAAP gross margin of 68.7%, compared to 68.3%
GAAP operating loss of $2.4 million, compared to $4.3 million
Non-GAAP operating income of $1.9 million, compared to $2.1 million



GAAP net loss per basic and diluted share of $0.02, compared to a net loss per basic and diluted share of $0.03
Non-GAAP net income per basic and diluted share of $0.01, compared to net income per basic and diluted share of $0.01
Cash provided by operations of $4.6 million, compared to cash provided by operations of $3.1 million

Total cash was $60.7 million as of June 30, 2021.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Business Outlook
For the full year 2021, the Company is reiterating its outlook and expects:
Revenue in the range of $135 million to $140 million
Non-GAAP operating income between income of $1 million and a loss of $4 million
Non-GAAP net income per share between income of $0.01 and a loss of $0.03, based on approximately 160 million to 161 million shares
For the third quarter of 2021, the Company expects:
Revenue in the range of $33 million to $35 million

Quarterly Conference Call
Castlight Health senior management will host a conference call to discuss its second quarter 2021 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company’s Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can



be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367. The conference ID number for the live call and replay is 3859414.

About Castlight Health
Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system and live happier, healthier, more productive lives. As a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical and benefits experts to help members easily connect and engage with the right programs and care, at the right time. Castlight partners with Fortune 500 companies and health plans to transform employee and member benefits into one comprehensive health and wellbeing experience to deliver better health outcomes and maximize returns on healthcare investments.

For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures
To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude goodwill impairment, stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, capitalization and amortization of internal-use software, and lease exit and related charges.




We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance. However, these non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

The non-GAAP measures we provide may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the Company’s financial information in its entirety and not rely on a single financial measure.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2021 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software, are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Words such as "anticipates," "expects," "intends," "plans," "projects," "believes," "seeks," "estimates," "can,"



"may," "will," "would" and similar expressions identify such forward-looking statements. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. The forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies include, but are not limited to, statements regarding certain 2021 financial projections, and our expectations for our future business and financial performance. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission, including the risks set forth in our annual report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on February 24, 2021, and our quarterly reports on Form 10-Q, including the quarterly report for the three months ended June 30, 2021, when filed with the SEC. All forward-looking statements in this press release are expressly qualified in their entirety by these cautionary statements and are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements, except as required by law. 

Copyright 2021 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.






CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)
 
As of
June 30, 2021December 31, 2020
Assets
Current assets:
Cash and cash equivalents$60,706 $49,242 
Accounts receivable and other, net21,735 31,740 
Prepaid expenses and other current assets8,716 3,800 
Total current assets91,157 84,782 
Property and equipment, net4,485 5,321 
Restricted cash, non-current— 1,144 
Deferred commissions7,181 9,556 
Deferred professional service costs3,874 4,462 
Intangible assets, net5,814 7,930 
Goodwill41,485 41,485 
Operating lease right-of-use assets, net8,006 10,238 
Other assets106 1,855 
Total assets$162,108 $166,773 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$3,729 $5,145 
Accrued expenses and other current liabilities5,175 7,898 
Accrued compensation7,104 8,633 
Deferred revenue9,993 6,848 
Operating lease liabilities6,092 5,789 
Total current liabilities32,093 34,313 
Deferred revenue, non-current87 663 
Operating lease liabilities, non-current4,338 7,446 
Other liabilities, non-current335 485 
Total liabilities36,853 42,907 
Stockholders’ equity 125,255 123,866 
Total liabilities and stockholders’ equity $162,108 $166,773 





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
 
 Three Months Ended June 30,Six Months Ended June 30,
2021202020212020
Revenue:
Subscription$31,128 $34,289 $63,238 $72,672 
Professional services and other4,475 1,211 7,424 1,873 
Total revenue, net35,603 35,500 70,662 74,545 
Cost of revenue:
Cost of subscription(1)
7,977 8,819 16,076 19,051 
Cost of professional services and other(1)
4,181 3,942 8,838 8,183 
Total cost of revenue12,158 12,761 24,914 27,234 
Gross profit 23,445 22,739 45,748 47,311 
Operating expenses:
Sales and marketing(1)
7,208 7,683 14,121 18,155 
Research and development(1)
12,316 13,043 24,429 26,865 
General and administrative(1)
6,366 6,340 12,732 12,916 
Goodwill impairment— — — 50,300 
Total operating expenses25,890 27,066 51,282 108,236 
Operating loss(2,445)(4,327)(5,534)(60,925)
Other income, net56 123 149 386 
Net loss$(2,389)$(4,204)$(5,385)$(60,539)
Net loss per share, basic and diluted$(0.02)$(0.03)$(0.03)$(0.41)
Weighted-average shares used to compute basic and diluted net loss per share
158,951 150,078 157,872 149,475 

(1)Includes stock-based compensation expense as follows:
 Three Months Ended June 30,Six Months Ended June 30,
 2021202020212020
Cost of revenue:
Cost of subscription$222 $205 $479 $374 
Cost of professional services and other184 144 420 260 
Sales and marketing442 748 792 1,420 
Research and development1,060 1,314 2,129 2,477 
General and administrative1,262 858 2,457 1,924 





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 Three Months Ended June 30,Six Months Ended June 30,
 2021202020212020
Operating activities:
Net loss$(2,389)$(4,204)$(5,385)$(60,539)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization1,616 1,609 3,239 3,144 
Goodwill impairment— — — 50,300 
Stock-based compensation3,170 3,269 6,277 6,455 
Amortization of deferred commissions1,228 1,536 2,568 3,919 
Amortization of deferred professional service costs567 732 1,147 1,657 
Non-cash operating lease expense1,125 1,231 2,232 2,631 
Other19 — 19 
Changes in operating assets and liabilities:
Accounts receivable and other, net3,300 4,898 10,005 (1,778)
Deferred commissions(219)(602)(193)(920)
Deferred professional service costs(221)(213)(521)(629)
Prepaid expenses and other assets932 (330)(2,023)(824)
Accounts payable(699)(2,739)(1,458)(10,201)
Operating lease liabilities(1,416)(1,100)(2,805)(2,616)
Accrued expenses and other liabilities(1,561)(1,530)(1,943)(1,511)
Deferred revenue(3,177)(811)2,569 2,762 
Accrued compensation2,349 1,351 (1,529)(3,114)
Net cash provided by (used in) operating activities4,624 3,097 12,199 (11,262)
Investing activities:
Purchase of property and equipment(33)(2,035)(245)(3,299)
Purchase of marketable securities— (1,005)— (2,994)
Sales of marketable securities— 2,001 — 2,001 
Maturities of marketable securities— 5,000 — 17,400 
Net cash (used in) provided by investing activities(33)3,961 (245)13,108 
Financing activities:
Proceeds from exercise of stock options98 — 226 155 
Proceeds from ESPP offering— — 233 186 
Principal payments on long-term debt(465)(465)(930)(930)
Net cash used in financing activities(367)(465)(471)(589)
Effect of of exchange rate changes on cash, cash equivalents, and restricted cash(19)— (19)— 
Net increase (decrease) in cash, cash equivalents and restricted cash
4,205 6,593 11,464 1,257 
Cash, cash equivalents and restricted cash at beginning of period
57,645 39,006 50,386 44,342 
Cash, cash equivalents and restricted cash at end of period$61,850 $45,599 $61,850 $45,599 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$60,706 $44,274 $60,706 $44,274 
Restricted cash included in Prepaid expenses and other current assets1,144 181 1,144 181 
Restricted cash, non-current— 1,144 — 1,144 
Total cash, cash equivalents and restricted cash$61,850 $45,599 $61,850 $45,599 


CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

Three Months EndedSix Months Ended
June 30, 2021March 31, 2021June 30, 2020June 30, 2021June 30, 2020
Gross profit:
GAAP gross profit subscription$23,151 $24,011 $25,470 $47,162 $53,621 
Stock-based compensation222 257 205 479 374 
Amortization of internal-use software79 79 79 158 105 
Amortization of intangibles530 530 530 1,060 1,060 
Reduction in workforce— — 221 — 221 
Non-GAAP gross profit subscription$23,982 $24,877 $26,505 $48,859 $55,381 
GAAP gross margin subscription74.4 %74.8 %74.3 %74.6 %73.8 %
Non-GAAP gross margin subscription77.0 %77.5 %77.3 %77.3 %76.2 %
GAAP gross profit (loss) professional services$294 $(1,708)$(2,731)$(1,414)$(6,310)
Stock-based compensation184 236 144 420 260 
Reduction in workforce— — 317 — 317 
Non-GAAP gross profit (loss) professional services$478 $(1,472)$(2,270)$(994)$(5,733)
GAAP gross margin professional services6.6 %(57.9)%(226)%(19.0)%(337)%
Non-GAAP gross margin professional services10.7 %(49.9)%(187)%(13.4)%(306)%
GAAP gross profit $23,445 $22,303 $22,739 $45,748 $47,311 
Impact of non-GAAP adjustments1,015 1,102 1,496 2,117 2,337 
Non-GAAP gross profit $24,460 $23,405 $24,235 $47,865 $49,648 
GAAP gross margin 65.9 %63.6 %64.1 %64.7 %63.5 %
Non-GAAP gross margin 68.7 %66.8 %68.3 %67.7 %66.6 %
Operating expense:
GAAP sales and marketing$7,208 $6,913 $7,683 $14,121 $18,155 
Stock-based compensation(442)(350)(748)(792)(1,420)
Amortization of intangibles(528)(528)(528)(1,056)(1,056)
Reduction in workforce— — (334)— (334)
Non-GAAP sales and marketing$6,238 $6,035 $6,073 $12,273 $15,345 
GAAP research and development$12,316 $12,113 $13,043 $24,429 $26,865 
Stock-based compensation(1,060)(1,069)(1,314)(2,129)(2,477)
Reduction in workforce— — (658)— (658)
Certain legal expenses— — — — 191 
Capitalization of internally developed software— — — — 21 
Non-GAAP research and development$11,256 $11,044 $11,071 $22,300 $23,942 
GAAP general and administrative$6,366 $6,366 $6,340 $12,732 $12,916 
Stock-based compensation(1,262)(1,195)(858)(2,457)(1,924)
Amortization of intangibles— — — — (17)
Reduction in workforce— — (497)— (497)
Non-GAAP general and administrative$5,104 $5,171 $4,985 $10,275 $10,478 
GAAP goodwill impairment$— $— $— $— $50,300 


CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

Goodwill impairment— — — — (50,300)
Non-GAAP goodwill impairment$— $— $— $— $— 
GAAP operating expense$25,890 $25,392 $27,066 $51,282 $108,236 
Impact of non-GAAP adjustments(3,292)(3,142)(4,937)(6,434)(58,471)
Non-GAAP operating expense$22,598 $22,250 $22,129 $44,848 $49,765 
Operating income (loss):
GAAP operating loss$(2,445)$(3,089)$(4,327)$(5,534)$(60,925)
Impact of non-GAAP adjustments4,307 4,244 6,433 8,551 60,808 
Non-GAAP operating income (loss) $1,862 $1,155 $2,106 $3,017 $(117)
Net income (loss) and net income (loss) per share:
GAAP net loss$(2,389)$(2,996)$(4,204)$(5,385)$(60,539)
Total pre-tax impact of non-GAAP adjustments4,307 4,244 6,433 8,551 60,808 
Non-GAAP net income $1,918 $1,248 $2,229 $3,166 $269 
GAAP net loss per share, basic and diluted$(0.02)$(0.02)$(0.03)$(0.03)$(0.41)
Non-GAAP net income per share, basic and diluted$0.01 $0.01 $0.01 $0.02 $— 
Shares used in basic and diluted net loss per share computation158,951 156,781 150,078 157,872 149,475 





Castlight Media Contact:
Caroline Kawashima
press@castlighthealth.com
415-246-0313



Castlight Investor Contact:
ir@castlighthealth.com
443-213-0500






EX-101.SCH 3 cslt-20210803.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cslt-20210803_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 cslt-20210803_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image1.jpg begin 644 image1.jpg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end XML 7 cslt-20210803_htm.xml IDEA: XBRL DOCUMENT 0001433714 2021-08-03 2021-08-03 false 0001433714 8-K 2021-08-03 CASTLIGHT HEALTH, INC. DE 001-36330 26-1989091 150 Spear Street Suite 400 San Francisco CA 94105 415 829-1400 Class B Common Stock, par value $0.0001 per share CSLT NYSE false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 03, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 03, 2021
Entity Registrant Name CASTLIGHT HEALTH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36330
Entity Tax Identification Number 26-1989091
Entity Address, Address Line One 150 Spear Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94105
City Area Code 415
Local Phone Number 829-1400
Title of 12(b) Security Class B Common Stock, par value $0.0001 per share
Trading Symbol CSLT
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001433714
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.castlighthealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cslt-20210803.htm cslt-20210803.xsd cslt-20210803_lab.xml cslt-20210803_pre.xml exh991-pressreleaseq221.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cslt-20210803.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cslt-20210803.htm" ] }, "labelLink": { "local": [ "cslt-20210803_lab.xml" ] }, "presentationLink": { "local": [ "cslt-20210803_pre.xml" ] }, "schema": { "local": [ "cslt-20210803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cslt", "nsuri": "http://www.castlighthealth.com/20210803", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cslt-20210803.htm", "contextRef": "i4eea679ebbdf40f4ae2905d8af59b51d_D20210803-20210803", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.castlighthealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cslt-20210803.htm", "contextRef": "i4eea679ebbdf40f4ae2905d8af59b51d_D20210803-20210803", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001433714-21-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001433714-21-000022-xbrl.zip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